fluticasone furoate

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Alisade has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

This EPAR was last updated on 18/10/2011

Authorisation details

Product details
Agency product number
Active substance
fluticasone furoate
International non-proprietary name (INN) or common name
fluticasone furoate
Therapeutic area (MeSH)
  • Rhinitis, Allergic, Perennial
  • Rhinitis, Allergic, Seasonal
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Glaxo Group Ltd.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Glaxo Group Limited
Greenford Road
Greenford, Middx UB6 0NN
United Kingdom

Product information

17/02/2010 Alisade - EMEA/H/C/001019 - IB/0007

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Nasal preparations

Therapeutic indication

Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.

Assessment history

How useful was this page?

Add your rating